BioSpace News Archive

Single intravenous dose phase 1 trial showed that AIC649 was safe and well tolerated in all dose groups

Cellmid Limited today advised that the Share Purchase Plan (“SPP”) announced on 31 July 2018 with an offer price of $0.38 has now closed.

Part 1 top-line data of the NOX-A12 trial to be presented at the September ‘Fourth International Cancer Immunotherapy Conference’

A randomized, placebo and gold-standard controlled clinical trial, investigating the treatment of incipient buccal caries lesions with CURODONT™ REPAIR was presented at the IADR 2018 in London. In this study Prof. Krejci and his team at the University of Geneva showed that the use of CURODONT™ REPAIR is superior to that of fluoride varnish or a placebo treatment.

MagForce AG today announced its participation in nine upcoming scientific and investor conferences in the second half of 2018

CrystalGenomics, Inc. announced today that they have signed an Export Agreement with Apsen Farmacêutica for the commercialization of Acelex® (polmacoxib) in Brazil.

Penumbra, Inc. today announced it has closed on the acquisition of a controlling interest in its joint venture, MVI Health Inc.

TissUse has signed a collaboration agreement with Bayer to develop a highly innovative liver-endocrine tissues assay using TissUse’s Multi-Organ-Chip (MOC) technology.

Development collaboration integrates Sartorius Stedim Biotech’s BIOSTAT® STR bioreactors and Repligen’s XCell™ ATF cell retention control technology

MMJ PhytoTech Limited is pleased to note the attached three news releases by MediPharm Labs Inc (“MediPharm”) providing the details of three customer contracts signed over the past month or so and ahead of its listing on the TSX Venture Exchange (“TSX-V”) expected later this month.